Bazinaprine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bazinaprine
Bazinaprine.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C17H19N5O
Molar mass 309.366 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro.[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.[2]

See also[edit]

References[edit]

  1. ^ Kan, JP; Steinberg, R; Leclercq, J; Worms, P; Biziere, K (1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: Evidence for selective and reversible inhibition of monoamine oxidase type a in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44. doi:10.1111/j.1471-4159.1988.tb10584.x. PMID 3346672. 
  2. ^ Kan, JP; Steinberg, R; Mouget-Goniot, C; Worms, P; Bizière, K (1987). "SR 95191, a selective inhibitor of type a monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition". The Journal of Pharmacology and Experimental Therapeutics. 240 (1): 251–8. PMID 3100771.